14. Jul 2026
Description
(AWP Alliance News) - Roche Holding AG launched the cobas HDV test, positioning it as the first high-throughput, fully automated hepatitis D assay as drugmakers roll out new treatments that increase demand for standardized monitoring. The launch targets a market where testing has relied on manual methods or lab-developed assays, creating an opening for Roche to consolidate share through scale and consistency.
The company expects the test to expand access by leveraging its installed base of cobas 5800, 6800, 8800 systems in laboratories worldwide. Hepatitis D affects about 12 million people globally, supporting a sizable screening and follow-up opportunity tied to chronic liver disease management.
https://www.publicnow.com/view/EEFB4F4F3CEEA49F0A1E47FD8FAF30CBAE1E3FB5…
Disclaimer: This news brief was created using generative artificial intelligence. Roche Holding AG published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.
